Research Papers:

Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway

PDF |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:50747-50760. https://doi.org/10.18632/oncotarget.17096

Metrics: PDF 917 views  |   HTML 1317 views  |   ?  

An Hu, Jing-Juan Huang _, Jing-Fei Zhang, Wei-Jun Dai, Rui-Lin Li, Zhao-Yang Lu, Jun-Li Duan, Ji-Ping Li, Xiao-Ping Chen, Jing-Ping Fan, Wei-Hua Xu and Hong-Liang Zheng


An Hu1, Jing-Juan Huang2, Jing-Fei Zhang1, Wei-Jun Dai1, Rui-Lin Li3, Zhao-Yang Lu3, Jun-Li Duan3, Ji-Ping Li4, Xiao-Ping Chen1, Jing-Ping Fan1,5, Wei-Hua Xu1 and Hong-Liang Zheng6

1Department of Otolaryngology, Gongli Hospital, Second Military Medical University, Pudong New Area, Shanghai, 200135, China

2Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China

3Department of Gerontology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China

4Department of Otolaryngology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong New Area, Shanghai, 200127, China

5Department of Otolaryngology-Head and Neck Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China

6Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

Correspondence to:

Jing-Juan Huang, email: hjjxinhua@163.com

Keywords: cell cycle arrest, apoptosis, ATM/Chk2/p53 signal pathway, head and neck squamous cell carcinoma, curcumin

Received: March 20, 2016     Accepted: March 31, 2017     Published: April 13, 2017


Studies have demonstrated that curcumin (CUR) exerts its tumor suppressor function in a variety of human cancers including head and neck squamous cell carcinoma (HNSCC). However, the exact underlying molecular mechanisms remain obscure. Here, we aim to test whether CUR affects ATM/Chk2/p53 signaling pathway, leading to the induction of cell cycle arrest, inhibition of angiogenesis of HNSCC in vitro and in vivo. To this end, we conducted multiple methods such as MTT assay, Invasion assay, Flow cytometry, Western blotting, RT-PCR, and transfection to explore the functions and molecular insights of CUR in HNSCC. We observed that CUR significantly induced apoptosis and cell cycle arrest, inhibited angiogenesis in HNSCC. Mechanistically, we demonstrated that CUR markedly up-regulated ATM expression and subsequently down-regulated HIF-1α expression. Blockage of ATM production totally reversed CUR induced cell cycle arrest as well as anti-angiogenesis in HNSCC. Moreover, our results demonstrated that CUR exerts its antitumor activity through targeting ATM/Chk2/p53 signal pathway. In addition, the results of xenograft experiments in mice were highly consistent with in vitro studies. Collectively, our findings suggest that targeting ATM/Chk2/p53 signal pathway by CUR could be a promising therapeutic approach for HNSCC prevention and therapy.

Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma <i>in vitro</i> and <i>in vivo</i> through ATM/Chk2/p53-dependent pathway | Hu | Oncotarget


Head and neck squamous cell carcinoma affects 600,000 people worldwide annually, including 42,000 in the United States [1]. Although remarkable progresses in treatment modalities in the past few years, the survival rate of HNSCC is less than satisfactory [2]. Close to half of these (30 to 50%) patients develop local recurrence and another 10–40% of patients develop distant metastasis due to field cancerization [3, 4]. Therefore, identifying more effective agents to improve therapeutic intervention for HNSCC patients and better understanding the potential molecular mechanisms of this disease are crucial [5].

Preservation of genomic integrity is a vital process for cell homeostasis [6]. Indeed, failure to accurately repair DNA damage has been correlated with numerous pathologies including cancer [6, 7]. In response to DNA damage, the ataxia-telangiectasia mutated (ATM) is activated through autophosphorylation of the Ser1981 residue and activates the distal transducer kinase checkpoint kinase 2 (Chk2), resulting in G2/M checkpoint initiation [6]. Others have reported that p53 was identified as important mediator of angiogenesis [8]. Evidence also supported that p53 up-regulates murine double minute 2-induced ubiquitination of the HIF-1α [9]. Therefore, we tried to explore the potential molecular mechanisms of ATM/Chk2/p53 signal pathway as a mediator of G2/M arrest and angiogenesis of HNSCC.

Curcumin (CUR) is the primary active ingredient of turmeric, which has been used in Chinese medicine over the years [10]. Accumulating evidences suggest that CUR shows its anti-tumor activity by modulating various targets either through direct interaction or through modulation of gene expression [11, 12]. Moreover, CUR has been demonstrated to possess direct antiangiogenic activity in vivo [1315]. Further study showed that CUR exerted its antitumor activity involved in reactivation of receptor activator of NF-κB and inactivation of STAT3 in glioblastoma cells [16]. Additionally, CUR was discovered to suppress the cell growth through inhibition of histone deacetylase 4 (HADC4) and NF-κB pathways in medulloblastoma cells [17, 18]. Although many investigations have demonstrated the molecular basis of CUR-mediated cell growth inhibition, the underlying role has not been fully elucidated. Based on the above considerations, the objective of this present investigation was to explore the effect of CUR on ATM/Chk2/p53 signaling pathway in HNSCC.


CUR inhibited proliferation of HNSCC cells in vitro

To address the probable anticancer mechanism of CUR via ATM/Chk2/p53-dependent signal pathway in vitro, we first evaluated cell proliferation in cell lines. Human HNSCC cell lines (HEp-2, SCC-15, FaDu cells) were cultured with 5 μM or 10 μM of CUR for 36 hours, then analyzed for the growth inhibitory effects using MTT assay. 10 μM CUR inhibited cell lines proliferation at rates of 55–75% to those untreated cells (Figure 1A1C; P < 0.01; n = 3). The expression level of proteolytic cleavage of PARP was obviously up-regulated in CUR-treated cell lines (Figure 1D1E; P < 0.01; n = 3). Moreover, KU55933(a specific inhibitor of ATM) partially reversed the CUR mediated cell viability attenuation. After treatment with 10 μM KU55933, the apoptosis rates of cell lines were dramatically decreased (Figure 1F).

Effect of CUR on the proliferation of HNSCC cells in vitro.

Figure 1: Effect of CUR on the proliferation of HNSCC cells in vitro. HNSCC cells were treated with different concentrations of CUR for 36 h. The effect of CUR on the proliferation of these cells was analyzed by MTT assay. (AC) Cell viability assays measuring growth and proliferation were performed in HEp-2, SCC-15, FaDu cells. A significant concentration-dependent decrease in viability of all cell lines was noted in response to treatment with CUR. 10 μM CUR inhibited cell lines growth at rates about 55–75% to those of control cells (P < 0.01; n = 3). (DE) Cell lines were treated with CUR (10 μM) and harvested. Then whole cell lysates were subjected to Western Blot analysis with anti-PARP, or anti-GAPDH. Moreover, treatment of cell lines with CUR triggered a marked increase in proteolytic cleavage of PARP (P < 0.01; n = 3). (F) After treatment with 10 μM KU55933, the apoptosis rate was significant reduced in cell lines. Blots shown are representative of three independent experiments. Data were expressed as mean ± SD. **P < 0.01, versus control group. (FL, full length; CF, cleaved fragment).

CUR caused apoptosis of HNSCC and induced activation of ATM mediated signaling pathways

Results of HNSCC proliferation assay also indicated that CUR not only inhibited cells proliferation, but also caused cells step into death. In order to clarify apoptosis or necrosis, we conducted Annexin V-FITC/PI assay and the results determined by flow cytometry showed that percent of apoptosis cells of HNSCC was increased apparently after treatment with CUR (Figure 2A2F), indicating that CUR has the ability to induce apoptosis of HNSCC. Annexin V-FITC/PI assay indicated that 10 μM CUR treatment for 36 h induced significant apoptosis in cell lines. As shown in Figure 2A2C, after treatment with CUR (10 μM), the cells lines showed apoptosis rate about 17.20%, 19.54% and 21.60%. And after exposure to 10 μM KU55933, three HNSCCs (HEp-2, SCC-15, FaDu cells) had similar lower levels of apoptosis rate than the control cells (Figure 2D2F).

Annexin-V/PI staining showed that CUR treatment induced apparent apoptosis in HEp-2, SCC-15, FaDu cells.

Figure 2: Annexin-V/PI staining showed that CUR treatment induced apparent apoptosis in HEp-2, SCC-15, FaDu cells. (AC) Annexin-V/PI staining showed that 10 μM CUR treatment for 36 h induced apparent apoptosis in cell lines. (DF) After treatment with CUR, the cells lines showed apoptosis at rates of 17.20%, 19.54% and 21.60%, respectively. Cells lines were treated with CUR in the presence or absence of the ATM inhibitor KU55933 for 24 h, followed by assessment for cell viability using MTT assays. After treatment with KU55933, the apoptosis rate was significantly reduced, not only in HEp-2 cells group, but also in SCC-15 and FaDu cells group.

CUR mediated DNA damage caused G2/M arrest and targeted ATM mediated signaling pathways

To demonstrate the potential role of CUR on the cell cycle distribution, the lysates were detected by flow cytometry. We found that the proportion of G2/M phase was 21.36%, 26.43%, and 31.32%, respectively, after treatment with 1, 5, and 10 μM of CUR for 24 h. For the control group, the frequency of G2/M cell cycle phase was 13.74%. The percentage of HEp-2 cell of G2/M cell cycle phase is remarkable up-regulation while that of cells in the G1-phase is decreased with the increasing concentration of CUR, as comparing with that in the control cells (Figure 3A3D, P < 0.01, n = 3). These data indicated that CUR arrested cell cycle of HEp-2 cells in G2/M phase. To determine if CUR could mediate DNA-damage, the expression of key molecules were examined by western blot analysis. We observed an increased in phospho-H2A.X, which is the indicator of DNA double-strand breaks (DSB). Meanwhile, our present investigation indicate that CUR treatment obviously down-regulated the expression of DNA polymerase β1 (Figure 3E). Intriguingly, CUR treatment enhanced the expression of pATM without change in the protein abundance in HEp-2 cells. At the same time, we observed substantial phosphorylation of Cdc25C (Ser-216) after treatment of CUR in HEp-2 cells (Figure 3E). Exposure of HEp-2 cells with 10 μM CUR for 24 h dramatically decreased the protein abundance of Cyclin B1 compared to control cells. However, protein level of Cdc25C was similar to control group (Figure 3F). Based on the above analysis, we summarized the potential mechanism by which CUR causes cell cycle halt in HNSCCs in Figure 3G.

Role of ATM/Chk2/p53 in CUR mediated G2/M cell cycle arrest.

Figure 3: Role of ATM/Chk2/p53 in CUR mediated G2/M cell cycle arrest. HEp-2 cells were treated with or without CUR for 24 h. Cells were collected and analysed for cell cycle distribution by flow cytometry. (AD) CUR increased the proportion of cells in G2/M phase and decreased that in the G1 phase, compared with the control group (*P < 0.01). FCM analysis showed CUR arrested HEp-2 cell cycling in the G2/M phase. (E) We observed an increased phosphorylation of H2A.X at Ser-139. At the same time, our results show that CUR treatment decreased the expression of DNA polymerase β1. (F) Treatment of HEp-2 cells with CUR increased the phosphorylation of ATM at Ser-1981. On the other hand, substantial phosphorylation of Cdc25C at Ser-216 was observed in HEp-2 cells treated with CUR. Exposure of HEp-2 cells with 10 μM CUR for 24 h significantly reduced the expression of Cyclin B1. (G) CUR causes cell cycle arrest at the G2/M phase. CUR induces DNA damage and activation of ATM, which phosphorylates H2A.X and CHK2 to induce cell cycle arrest at the G2/M phase by Cdc25c inhibition. CUR mediated effects may occur through a molecular mechanism dependent of ATM/Chk2/p53 signal pathway activation and confirmed our data suggesting the potent anticancer activity of CUR. Data were expressed as mean ± SD. **P < 0.01.

CUR-induced G2/M arrest of HNSCC is associated with activation of ATM/Chk2/p53 signal transduction cascade

For the sake of more intuitive experimental results, we analyzed protein expression of ATM, pATM and Chk2 using Western blotting. After exposure to CUR, except for pATM (Figure 4A4B), the expression level of Chk2 and ATM in HEp-2 cells were all significantly increased (Figure 4C4D). Therefore, these results implied that CUR induced apoptosis in HEp-2 cells through an ATM/Chk2/p53-dependent pathway, at least partially. As shown in Figure 4E, the mRNA expression of ATM and Chk2 was borderline decreased by CUR pretreatment of HEp-2 cells (p > 0.05). Western immunoblot analysis of p53 and p21 showed a marked increase in protein state in CUR treated HEp-2 cells (Figure 4F4G). CUR pretreatment of HEp-2 cells decreased Cdk1 protein abundance at 12 h, with enhancing effect at 24 h (Figure 4G).

CUR-induced apoptosis is associated with activation of ATM/Chk2/p53 signal pathway.

Figure 4: CUR-induced apoptosis is associated with activation of ATM/Chk2/p53 signal pathway. (AB) HEp-2 cells were treated with CUR (10 μM) for the indicated times and harvested. CUR triggered a significant increase in pATM levels in HEp-2 cells. (CD) Examination of Chk2 showed a marked increase in phosphorylation in response to CUR. (E) The mRNA expression of ATM and Chk2 was borderline decreased by CUR pretreatment of HEp-2 cells (p > 0.05). (FG) Western blot analysis using antibodies specific against p53 and p21 showed a marked increase in protein state of p53 and p21 in CUR treated HEp-2 cells. And CUR pretreatment of HEp-2 cells decreased Cdk1 expression level at 12 h, with increasing effect at 24 h. Results are mean ± SD of three independent experiments (n = 3; P < 0.005).

CUR inhibited tube formation and blocked migration of Human umbilical vein endothelial cells (HUVECs) in vitro

In order to evaluate the anti-angiogenic and anti-migration potential of CUR and its role of action by means of ATM/Chk2/p53 signal pathway, transwell migration assay, wound healing assays and tubule formation assays were conducted to measure transmigration and tubule formation of HUVECs. Our results showed that CUR markedly inhibited HUVECs migration (Figure 5A5B). To demonstrate the anti-angiogenic potential of CUR, we next performed Matrigel angiogenesis assay in vitro with HUVECs. Capillary-like tubule formation was significantly decreased in CUR treated cells in a dose-dependent fashion (Figure 5C5D). Furthermore, scarification assay revealed that migration of HUVECs was significantly suppressed by CUR without loss of cell viability (Figure 5E5F). A significant reduction of HIF-1α and VEGF was observed in HUVECs receiving CUR treatment (Figure 5G5I). After treated with CUR for 24 hours, phosphorylation of Akt and Erk were observed to be decreased apparently (Figure 5J5K).

CUR blocks migration and tubule formation of HUVECs in vitro.

Figure 5: CUR blocks migration and tubule formation of HUVECs in vitro. (AB) CUR significantly inhibited HUVECs migration, as evidenced by a decrease in the number of crystal violet-stained cells. 10 μM CUR pretreatment of HUVECs inhibited transmigration, which was statistically significant difference to the effect of control group (scale bars, 10 μm). (CD) HUVECs were seeded in 96-well culture plates precoated with Matrigel; and then examined for tubule formation using an inverted microscope. Tubule formation was markedly decreased in a dose-dependent manner in CUR-treated cells (scale bars, 100 μm). (E) Results of wound healing assay, HUVECs migration ratio after CUR treatment for 8 hours. (F) HUVECs were treated with or without CUR at the indicated concentrations, followed by assessment for cell viability using MTT assays. Raw data from MTT assays were normalized to the % of viable cells in control versus CUR-treated carcinoma cells. (GK) HUVECs were treated with CUR for 24 hours, then cell lysates were collected and western blot was conducted for the indicated proteins (**P < 0.01 vs control).

CUR suppressed HNSCC tumor growth in xenograft nude mice model (In vivo)

In order to further validate the interaction between CUR and ATM/Chk2/p53 signal pathway in vivo, xenograft nude mice model was developed to investigate underlying anti-angiogenesis activity of CUR. In our xenograft nude mice model, we observed that the nude mice tumor grew significantly slower in the CUR treated mice than that of the vector tumor model (Figure 6A6C), which confirms the viewpoint that CUR decelerates tumor growth in vivo. HEp-2 cells were injected into one side of ventral flanks subcutaneously of female nude mice. The volumes of tumor were gauged every day from two weeks after transplantation. In contrast, we had observed no significant difference of body weights between different groups (Figure 6D), which demonstrates CUR has the potential against the tumor growth and shows no toxicity to tumor-bearing mice. Moreover, we found a dramatically decrease in Ki-67-positive cells in tumor sections from CUR-treated mice compared with control mice. Blockage of ATM production totally reversed CUR induced cell apoptosis in the xenografted tumor (Figure 6E6H). In line with our in vitro findings, CUR significantly increased p-ATM expression in the transplanted tumor burdens (Figure 6I, Supplementary Figure 1).The xenografted tumor sections were also used to evaluate the effect of CUR on phosphorylation of Chk1 and Cdc25c, and the results showed that CUR obviously induced phosphorylation of Chk1 and Cdc25c (Figure 6J6L), which indicated that CUR can induce the activation of ATM and target ATM mediated signaling pathways.

In vivo effects of CUR on HNSCC growth.

Figure 6: In vivo effects of CUR on HNSCC growth. Female nude mice were subcutaneously injected into one side of ventral flanks with HEp-2 cells. The tumor volumes were measured every day from day 14 after transplantation (AB) and weight (C) of tumors at day 35 posttransplantation are shown. (D) No significant difference of body weights was observed between different groups. (EH) Tumors were removed from CUR-treated or control untreated mice, followed by immunofluorescence analysis with antibodies against cleaved-caspase-3 and Ki-67. (I) Examination of the xenografted tumor sections showed that CUR increased the number of p-ATM positive cells. (JL) Furthermore, a significant increase in cell cycle protein Chk1 and Cdc25c was also noted in tumor sections from CUR-treated mice relative to control mice. GAPDH was used as an internal loading control. The data are expressed as mean ± SD, and significant differences from the control are indicated by **P < 0.01 (scale bars, 100 μm).

CUR decreased tumor microvessel density in tumor-bearing mice

Further analysis of histology indicates that tumor-bearing mice with CUR treatment presented lower CD31 expression and MVDs than did vehicle infected tumors (Figure 7A7B). Immunofluorescence analysis of tumor sections showed that CUR significantly decreased HIF-1α expression compared to that of the untreated group (Figure 7C7D), which indicated CUR could inhibit tumor angiogenesis. Since VEGF is known to significantly induce pathological angiogenesis in tumors, the effect of CUR on VEGF and tumor angiogenesis was investigated. And we observed a dramatically decrease of VEGF in tumor sections from tumor-bearing mice receiving CUR treatment compared with untreated mice (Figure 7E, Supplementary Figure 2). And we further examined the role of CUR on MMP-9 and MMP-2 in xenograft nude mice model. As shown in Figure 7F, the expression level of MMP-9 and MMP-2 was dramatically down-regulated by CUR pretreatment of xenograft cells. Blockage of ATM production totally reversed CUR suppressed angiogenesis in the xenografted tumor (Figure 7G).

In vivo effects of CUR on HIF-1&#x03B1; expression and angiogenesis.

Figure 7: In vivo effects of CUR on HIF-1α expression and angiogenesis. (AB) The representative IHC staining images (scale bars, 100 μm) and the expression scores of CD31 and the numbers of MVD in HEp-2 cells originated tumors at day 35 after injection. (CD) Immunofluorescence analysis of tumor sections showed that CUR significantly decreased HIF-1α expression compared to that of the untreated group. (E) A significant reduction of VEGF in tumor was observed in mice receiving CUR treatment relative to untreated mice. (F) Pretreatment of xenograft mice model with CUR resulted in inhibition of MMP-2 and MMP-9 production. Blockade of ATM partially reversed CUR-induced decrease in MMP-2 and MMP-9 production. These results indicate that CUR attenuates VEGF, MMP-2 and MMP-9 protein expression. (G) Smooth muscle actin (SMA) shows exclusive staining of the smooth muscles cells within veins and arteries and does not overlap with CD34 FITC staining which is localized in the endothelial lining of vessels. Data are mean ± SD in six mice in an independent experiment. **represents p < 0.01 compared with vehicle.


Several studies have indicated that cells engage a complex set of events in response to DNA damage [6]. These events bring about the remove of the damage and also halt or slow down cell cycle progression until the damage has been repaired [6, 19]. The antitumor potential of CUR originates from its ability to block migration of many tumor cell lines, increase the expression of p53, p21 [2024]; decrease the expression of Egr-1, activator protein-1 and NF-κB; suppress the expression of matrix metalloprotein-9, chemokines, LOX, cyclo-oxygen-ase-2, NOS, TNF, uPA and cyclin D1; suppress the activity of growth factor receptors; and reduce the expression of c- JNKs [2531]. In our study, CUR blocks proliferation of HNSCC cells in vitro. This study reflects that the ATM/Chk2/p53 signal pathway plays a key role in curcumin-mediated cell cycle arrest in the HNSCC. HNSCC cells viability was assessed and about 75% cell death was observed after CUR treatment.

CUR has been reported to induce apoptosis and cell cycle arrest in different carcinoma cells [3234]. In this study, we demonstrate that 5 μM CUR causes G2/M arrest in HNSCCs. We then examined the underling mechanism of DNA strand breaks induced G2/M halt by CUR in HNSCC. In addition, we found a decreased DNA polymerase-β and an up-regulation of p-H2A.X and p-ATM. Phosphorylation of H2A.X and ATM protein are indicators of DNA strand breaks and DNA polymerase beta plays an important role in DNA damage repair. And ATM is a member of PIKK that play a crucial role in the repair of DNA damage [35]. During DNA damage repair process, ATM is recruited at the DNA strand breaks sites and undergoes autophosphorylation at Ser-1981, meanwhile it triggers series of signal pathways via the phosphorylation of cell cycle proteins such as Chk2 at Thr-68 [36, 37]. Our findings indicate CUR stimulates ATM through phosphorylation at Ser-1981. The results of this study are consistent with previous findings in non-small cell lung cancer where kotomolide decreased proliferation via the activation of ATM [38]. To explore the potential role of ATM in CUR-induced G2/M halt, HNSCC cell lines were subjected to CUR in the presence or absence of KU55933, a biological inhibitor of ATM. Reduced expression of ATM obviously inhibited ATM phosphorylation at Ser-1981 induced by CUR and essentially prevented HNSCC cell lines from undergoing cell cycle arrest as well as apoptosis.

HUVECs play a role in vascular sprout and growth and often be used to evaluate anti-angiogenesis activity in vitro [39]. In the present study, HUVECs viability was assessed and < 5% cell death rate was found after CUR treatment, including the potential drug-induced suppression of tubule formation. We observed that CUR suppressed tubule formation of HUVECs through inhibiting HIF-1α, and it was consistent with previous studies [40, 41]. These findings indicate that CUR has the possibility to inhibit angiogenesis. In addition, several treatments have been studied in order to increase clinical therapeutic effect of anti-angiogenic therapy against hypoxic tumor chambers [42]. However, HIF-1α blockade inhibits pathological vessels as well as reduces healthy angiogenesis [43]. According to the results, decreased the expression of ATM is linked with angiogenesis and HIF-1α expression in HNSCC cells, suggestion that specific inhibitor regulating ATM pathway would be beneficial for suppressing tumor angiogenesis [44].

In summary, these experiments provide the potent evidence that CUR dramatically inhibited the proliferation of HNSCC via the activation of ATM/Chk2/p53 and suppressed angiogenesis by the inhibition of HIF-1α expression. Further study is necessary to figure out whether CUR contributes other possible molecular mechanisms through targeting ATM/Chk2/p53 pathway.


Cell culture and proliferation assay

In this study, all cell lines (HEp-2, SCC-15, FaDu) were purchased from Clonetics (San Diego, CA, USA) and were maintained in Dulbecco’s modified Eagle’s medium containing 1% penicillin and streptomycin, supplemented with 10% fetal bovine serum (FBS). 95% humidified air was generated by flushing a 5% CO2 mixture into the incubator. Supernatant and cell lysates were collected at 3 days after reseeding. A total of 3 × 104 cells per well were seeded onto fibronectin-coated 24-well plates, and proliferation assays were performed according to the manufacturer’s instructions. After pretreatment with 5 μM/10 μM CUR for 6, 12, 24 and 36 h, or left untreated. Then, cells were re-suspended and counted. CUR was obtained from Shanghai Laboratory Animal Co Ltd (SLAC, Shanghai, China). Each condition was assessed in triplicate.

Cell apoptosis assay

Cell apoptosis was quantified using the Annexin V/propidium iodide (PI) detection kit (Beyotime, Shanghai, China) and analyzed by flow cytometry. Cells (2 × 105/well) were plated in 6-well dishes and treated with 10 μM CUR or no CUR exposed to 10 μM KU55933 or no KU55933. After treatment, collected cells were incubated in 400 μl binding buffer with 5 μl Annexin V-FITC and 5 μl PI in dark for 15 min at room temperature.

Migration assay and wound healing assay (in vitro)

Transwell Insert Assays using Transwell migration chambers (BD Biosciences) with 6.5-mm-diameter polycarbonate filters ( 8 μm pore size) were utilized to measure migration as previously described [45]. In brief, cells were pretreated with CUR for 1–3 hours as indicated. Thereafter, the bottom chambers were filled with 600 μL of DMEM media containing all supplements. Cell lines (3 × 104 per well) were seeded in top chambers in 100 μL DMEM media without serum. HUVECs were seeded into six-well plates to reach a confluence, which was wounded with a yellow pipette tip. The plates were incubated as above and photographed at 24 h. The migrated cells were quantified by manual counting and five randomly chosen fields were analyzed for each well.

Capillary-like tubule structure formation assay (in vitro)

In vitro angiogenesis was assessed by Matrigel capillary-like tubule structure formation assay as described previously [46]. Matrigel-Matrix (BD Biosciences, Franklin Lakes, New Jersey, USA) was pipetted into pre-chilled 96-well plates (50 μL matrigel per well) and polymerized for 45 min at 37°C. HUVECs were seeded onto the solidified gel, and the endothelial tubes were counted under photomicroscope. Images were acquired under a fluorescent microscope (IX-71; Olympus, Tokyo, Japan) with 12.8 M pixel recording digital color cooled camera (DP72; Olympus). Capillary tubule branch points were counted in six randomly selected fields per well, and used as an index for tubule formation.

Xenograft tumor model (in vivo)

Animal care and experiments were performed in strict accordance with the “Guide for the Care and Use of Laboratory Animals” and the “Principles for the Utilization and Care of Vertebrate Animals” and were approved by the Experimental Animal Ethical Committee at Shanghai Jiao Tong University School of Medicine. All animal experiments were housed four per cage on a 12:12 light: dark cycle with free access to food and water. The xenograft tumor model was performed as previously described [47]. ATM-deficient mice and female athymic nude (nu/nu) mice (3–4 weeks old) were purchased from Shanghai Laboratory Animal Co Ltd (SLAC, Shanghai, China). The generation and genotyping of the ATM−/− and ATM+/− mice have been previously described [48]. The mice were bred and maintained under specific pathogen-free conditions in the Animal Facility, Shanghai Jiaotong University. HEp-2 (5 × 106) cells were inoculated subcutaneously into the right flank of nude mice. The volume of the implanted tumor was measured at every day with a vernier caliper, using the formula: V = L × W2/2; When tumors were measurable approximately one week after HEp-2 cells injection, mice were treated orally with vehicle alone (20% PEG400 deionized water) or CUR (200 mg/kg) for 4 weeks on a seven consecutive days/week schedule. The mice were sacrificed and the tumors were weighed 5 weeks after inoculation.

Quantitative real-time PCR of mRNAs

The expression of mRNAs was assayed using TaqMan mRNA reverse transcription assays (Applied Biosystems) following the manufacturer’s instructions as described previously [49]. The primers for ATM, Chk2 and GAPDH were used as showing in Table 1. The reaction conditions indicated in the manufacturer’s manual were used and the reaction mixtures were incubated at 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60ºC for 1 min. The ΔΔCt method for relative quantization was used to determine mRNA expression levels. The ΔCt value was calculated by subtracting the Ct of GAPDH from the Ct of the mRNA of interest. The ΔΔCt value was calculated by subtracting the ΔCt of the reference sample from the ΔCt of each sample. The fold-change was determined as 2−ΔΔCt.

Table 1: PCR primers used to amplify the mRNA


Forward primer (5′–3′)

Reverse primer (5′–3′)










Western blotting and protein quantification assay

Western blotting analyses were performed as described previously [50] using antibodies against specific protein. GAPDH was used as a loading control. Densitometry of protein bands was acquired using an EC gel documentation system (Alpha Innotec, Kasendorf, Germany), and bands were analysed using the spot densitometry analysis tool (Alpha Ease FC software, version, 4.1.0).

Immunohistochemistry and immunofluorescence antibody assay

Cancer tissue samples were processed for immunohistochemistry (IH) and immunofluorescence (IF) with activated caspase-3 (AC-3) and Ki-67 antibodies for the detection of apoptosis. Angiogenesis was assessed using the IHC staining of anti-CD31 antibody for nude mice cancerous tissues. Monolayers were rinsed once in phosphate-buffered saline (PBS), fixed with cold methanol for 30 min and blocked with 5% bovine serum albumin in PBS with Ca2+ and Mg2+ for 60 min. After further incubation for 15 min at 37°C, the fluorescence was measured using a fluorescence microscope (Olympus BX-40) and a Leica DFC 300FX camera. Analyses were performed by a single blinded researcher [50]. The stained slides were scored by two investigators according to the value of IRS systems.

Statistical analysis

All the statistical analyses were performed by the statistical package for social science (SPSS) (v. 13) (SPSS Institute). Statistical significance of differences observed in drug-treated versus control cultures was determined by the Student’s t test. Tumor volume in mice was measured using the GraphPad prism (GraphPad Software, SanDiego, CA, USA). The p values for comparison between line-linked groups were obtained by Student’s t test. All statistical tests were two-sided, and P < 0.05 was considered to be statistically significant.


We thank H. Jing-Juan and D. Jun-Li for designing the project. We thank L. Rui-Lin and L. Zhao-Yang for data analyses. We also thank C. Xiao-Ping and F. Jing-Ping for their technical assistance. All authors read and approved the manuscript. This study was funded by grants from the China National Natural Science Foundation (No.81602369 and No.81601505), Shanghai Pudong Youth Talent Project in Medicine (No.PWRq2015-21), and the Shanghai Jiaotong University Youth Project (No.YG2015QN47).


The authors declare no conflicts of interest.


1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277–300.

2. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004; 10:1956–62.

3. Azad AK, Bairati I, Samson E, Cheng D, Cheng L, Mirshams M, Savas S, Waldron J, Wang C, Goldstein D, Xu W, Meyer F, Liu G. Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. Cancer. 2012; 118:1554–65.

4. Lim W, Kim O, Jung J, Ko Y, Ha J, Oh H, Lim H, Kwon H, Kim I, Kim J, Kim M, Kim S, Kim BK, et al. Dichloromethane fraction from Gardenia jasminoides: DNA topoisomerase 1 inhibition and oral cancer cell death induction. Pharm Biol. 2010; 48:1354–60.

5. Zhu M, Yin F, Yang L, Chen S, Chen R, Zhou X, Jing W, Fan X, Jia R, Wang H, Zheng H, Zhao J, Guo Y. Contribution of TIP30 to chemoresistance in laryngeal carcinoma. Cell Death Dis. 2014; 5:e1468.

6. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010; 18:619–29.

7. Stracker TH, Usui T, Petrini JH. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst). 2009; 8:1047–54.

8. Nguyen PD, Tutela JP, Thanik VD, Knobel D, Allen RJ Jr, Chang CC, Levine JP, Warren SM, Saadeh PB. Improved diabetic wound healing through topical silencing of p53 is associated with augmented vasculogenic mediators. Wound Repair Regen. 2010; 18:553–59.

9. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000; 14:34–44.

10. Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer. 2009; 100:1425–33.

11. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008; 269:199–225.

12. Hasima N, Aggarwal BB. Cancer-linked targets modulated by curcumin. Int J Biochem Mol Biol. 2012; 3:328–51.

13. Bhandarkar SS, Arbiser JL. Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol. 2007; 595:185–95.

14. Thaloor D, Singh AK, Sidhu GS, Prasad PV, Kleinman HK, Maheshwari RK. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 1998; 9:305–12.

15. García V, Lara-Chica M, Cantarero I, Sterner O, Calzado MA, Muñoz E. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. Oncotarget. 2016; 7:4490–506. doi: 10.18632/oncotarget.6606.

16. Wu B, Yao X, Nie X, Xu R. Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. DNA Cell Biol. 2013; 32:292–97.

17. Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer. 2011; 11:144.

18. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer. 2011; 11:136.

19. d’Adda di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev. 2004; 18:1781–99.

20. Miao Y, Zhao S, Gao Y, Wang R, Wu Q, Wu H, Luo T. Curcumin pretreatment attenuates inflammation and mitochondrial dysfunction in experimental stroke: the possible role of Sirt1 signaling. Brain Res Bull. 2016; 121:9–15.

21. Shi D, Xu Y, Du X, Chen X, Zhang X, Lou J, Li M, Zhuo J. Co-treatment of THP-1 cells with naringenin and curcumin induces cell cycle arrest and apoptosis via numerous pathways. Mol Med Rep. 2015; 12:8223–28.

22. Patel PB, Thakkar VR, Patel JS. Cellular Effect of Curcumin and Citral Combination on Breast Cancer Cells: Induction of Apoptosis and Cell Cycle Arrest. J Breast Cancer. 2015; 18:225–34.

23. Lee AY, Fan CC, Chen YA, Cheng CW, Sung YJ, Hsu CP, Kao TY. Curcumin Inhibits Invasiveness and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Through Reducing Matrix Metalloproteinase 2, 9 and Modulating p53-E-Cadherin Pathway. Integr Cancer Ther. 2015; 14:484–90.

24. Baharuddin P, Satar N, Fakiruddin KS, Zakaria N, Lim MN, Yusoff NM, Zakaria Z, Yahaya BH. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep. 2016; 35:13–25.

25. Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim JT, Kim BY, Lee SJ, Choe YK, Kim DH, Kim SH, Chae SW, Kim KD, Lee HG. Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget. 2014; 5:519–529. doi: 10.18632/oncotarget.1714.

26. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, Faull KF, Srivatsan ES, Wang MB. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther. 2010; 9:2665–75.

27. Lin YC, Wu MH, Wei TT, Lin YC, Huang WC, Huang LY, Lin YT, Chen CC. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget. 2014; 5:298–308. doi: 10.18632/oncotarget.1628.

28. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014; 5:2736–49. doi: 10.18632/oncotarget.1932.

29. Hu A, Huang JJ, Li RL, Lu ZY, Duan JL, Xu WH, Chen XP, Fan JP. Curcumin as therapeutics for the treatment of head and neck squamous cell carcinoma by activating SIRT1. Sci Rep. 2015; 5:13429.

30. Chang PY, Peng SF, Lee CY, Lu CC, Tsai SC, Shieh TM, Wu TS, Tu MG, Chen MY, Yang JS. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Int J Oncol. 2013; 43:1141–50.

31. Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res (Phila). 2010; 3:331–38.

32. Blakemore LM, Boes C, Cordell R, Manson MM. Curcumin-induced mitotic arrest is characterized by spindle abnormalities, defects in chromosomal congression and DNA damage. Carcinogenesis. 2013; 34:351–60.

33. Basha R, Connelly SF, Sankpal UT, Nagaraju GP, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M, Simecka JW, El-Rayes B. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. J Nutr Biochem. 2016; 31:77–87.

34. Berrak O, Akkoc Y, Arisan ED, Coker-Gurkan A, Obakan-Yerlikaya P, Palavan-Unsal N. The inhibition of PI3K and NFkappaB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. Biomed Pharmacother. 2016; 77:150–60.

35. Nair RS, Kumar JM, Jose J, Somasundaram V, Hemalatha SK, Sengodan SK, Nadhan R, Anilkumar TV, Srinivas P. Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB). Sci Rep. 2016; 6:26631.

36. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 2000; 33:261–74.

37. Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, Sehested M, Lukas J, Bartek J. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 2001; 61:4990–93.

38. Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, Ding J. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther. 2008; 7:1440–49.

39. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, Galper JB. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev. 2006; 2:93–102.

40. Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun. 2002; 297:934–42.

41. Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, DE Lillo A, Laino L, Lo Muzio L. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med. 2015; 10:1615–23.

42. Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol. 2012; 9:378–90.

43. Okuno Y, Nakamura-Ishizu A, Otsu K, Suda T, Kubota Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med. 2012; 18:1208–16.

44. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012; 37:364–72.

45. Hu A, Huang JJ, Jin XJ, Li JP, Tang YJ, Huang XF, Cui HJ, Xu WH, Sun GB. Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway. Am J Cancer Res. 2014; 5:278–88.

46. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006; 355:1222–32.

47. Masuda T, Endo M, Yamamoto Y, Odagiri H, Kadomatsu T, Nakamura T, Tanoue H, Ito H, Yugami M, Miyata K, Morinaga J, Horiguchi H, Motokawa I, et al. ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. Sci Rep. 2015; 5:9170.

48. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996; 86:159–71.

49. Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, Tang YJ, Huang XF, Cui HJ, Sun GB. miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am J Transl Res. 2014; 6:604–13.

50. Huang JJ, Shi YQ, Li RL, Hu A, Zhou HS, Cheng Q, Xu Z, Yang ZM, Hao CN, Duan JL. Angiogenesis effect of therapeutic ultrasound on ischemic hind limb in mice. Am J Transl Res. 2014; 6:703–13.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17096